Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/oncotarget.10482 http://scihub22266oqcxt.onion/10.18632/oncotarget.10482 C5342462!5342462 !27409839     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27409839 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27409839 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Oncotarget 2016 ; 7 (34 ): 55924-55938 Nephropedia Template TP {{tp|p=27409839 |t=2016. FGFR3-TACC3 fusion in solid tumors: mini review |pdf=|usr=}}{{27409839 }} gab.com Text FGFR3-TACC3 fusion in solid tumors: mini review JO: Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=27409839 #FOAvip Fibroblast growth factor receptors (FGFR) are transmembrane kinase proteins with growing importance in cancer biology given the frequency of molecular alterations and vast interface with multiple other signaling pathways. Furthermore, numerous FGFR inhibitors in clinical development demonstrate the expanding therapeutic relevance of this pathway. Indeed, results from early phase clinical trials already indicate that a subset of patients with advanced tumors derive benefit from FGFR targeted therapies. FGFR gene aberrations and FGFR gene rearrangements are relatively rare in solid malignancies. The recently described FGFR3-TACC3 fusion protein has a constitutively active tyrosine kinase domain and promotes aneuploidy. We summarize the prevalence data on FGFR3-TACC3 fusions among different histological tumor types and the preliminary evidence that this rearrangement represents a targetable molecular aberration in some patients with solid tumors. Twit Text FOAVip FGFR3-TACC3 fusion in solid tumors: mini review ????Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=27409839 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27409839 #FOAvip English Wikipedia <ref>{{Cite pmid|27409839 }}</ref> FGFR3-TACC3 fusion in solid tumors: mini review #MMPMID27409839 Costa R ; Carneiro BA ; Taxter T ; Tavora FA ; Kalyan A ; Pai SA ; Chae YK ; Giles FJ Oncotarget 2016[Aug]; 7 (34 ): 55924-55938 PMID27409839 show ga Fibroblast growth factor receptors (FGFR) are transmembrane kinase proteins with growing importance in cancer biology given the frequency of molecular alterations and vast interface with multiple other signaling pathways. Furthermore, numerous FGFR inhibitors in clinical development demonstrate the expanding therapeutic relevance of this pathway. Indeed, results from early phase clinical trials already indicate that a subset of patients with advanced tumors derive benefit from FGFR targeted therapies. FGFR gene aberrations and FGFR gene rearrangements are relatively rare in solid malignancies. The recently described FGFR3-TACC3 fusion protein has a constitutively active tyrosine kinase domain and promotes aneuploidy. We summarize the prevalence data on FGFR3-TACC3 fusions among different histological tumor types and the preliminary evidence that this rearrangement represents a targetable molecular aberration in some patients with solid tumors. |*Gene Fusion [MESH] |Animals [MESH] |Humans [MESH] |Microtubule-Associated Proteins/*genetics [MESH] |Neoplasms/*genetics [MESH] |Receptor, Fibroblast Growth Factor, Type 3/*genetics [MESH]FGFR3-TACC3 fusion in solid tumors: mini review (epmc).pdf DeepDyve Pubget Overpricing